ESCRS - ACQUIRED BRAIN INJURY

ACQUIRED BRAIN INJURY

ACQUIRED BRAIN INJURY
Arthur Cummings
Published: Thursday, August 27, 2015

Informed consent, full consideration of temporary and non-invasive treatments as well as a ‘wait and see’ approach are key components of the optimal treatment of ocular issues caused by acquired brain injuries, according to Ian Marsh MD, Consultant Ophthalmic Surgeon, Aintree University Hospital NHS Foundation Trust, UK, who spoke at the 2015 Irish College of Ophthalmologists annual conference in Westport, Ireland.

Common acquired brain injury ocular issues include diplopia, nerve palsies, as well as acuity and visual field loss, he said, adding that occult perforation or retinal detachment may occur in some traumatic injuries. However, penetrating ocular injuries are not as common now from road traffic accidents due to the use of seatbelts and shatter-proof windscreens, he explained.

Dr Marsh recommended a multidisciplinary approach to assessing acquired brain injury patients, with a full assessment of visual apparatus as well as determination of the patient’s mental capacity.

“Because the discussion you are going to be having about any type of intervention you are going to do is going to be at a very complex level, and if they don’t have the mental capacity to take that in, that can be very difficult for you,” he said.

There are a number of “basic” visual treatment options, some short-term or reversible for acquired brain injury patients, as some ocular problems will recover in time or will need surgery later on, Dr Marsh explained. Basic treatment includes prisms, and occlusion using contacts, intraocular lenses (IOLs) and patches. However, he cautioned against using IOLs for occlusion in diabetic patients because of the need to be able to monitor the retina.

 

REALISTIC EXPECTATIONS

Botox injections also have significant therapeutic and diagnostic uses in these patients, Dr Marsh told the conference, particularly in the treatment of the various nerve palsies, and in pre-surgical simulation and postoperative diplopia testing.

“For example, in a patient with third nerve palsy who asks for an operation, using Botox you can simulate surgically what you are going to do and say: ‘that is what you are likely to have after I have done any intervention, do you want it or not?’, which also helps with informed consent,” he commented.

In sixth nerve palsy, spontaneous recovery is quite common. “In diabetics for example, about 80 per cent of them will recover spontaneously without any intervention,” Dr Marsh added.

Dr Marsh stressed the need for realistic expectations about surgical outcomes, in both doctors themselves and patients, and for informed consent. Specifically, he said patients with an ocular paresis do better than those with actual palsies.

 

Ian Marsh: Ian.marsh2001@gmail.com

Latest Articles
Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

Read more...

Diamonds in the Rough

The push for inclusivity in ophthalmology.

Read more...

Making Female Leadership More than a Moment

A remarkable global confluence of women in key positions.

Read more...

ESCRS Talks Technology at AAO

Europe adopts technological advances, US still waiting for lenses and lasers.

Read more...

Sorting Out Simultaneous Vision IOLs

The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.

Read more...

Big Advantages to Small-Aperture IOLs

Small-aperture IOLs offer superior image quality with increased range of focus.

Read more...

Prioritising Self-Care

Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.

Read more...

Valuing Clinical Trial Design

How inclusivity and diversity can enhance scientific accuracy in research.

Read more...

Knowing Iris Repair: Using Iridodiathermy in Iris Surgery

Prepare for decentred pupils and uneven irides in multiple situations.

Read more...

Neuroprotectant Treatment for MacTel Type 2

Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.

Read more...